Cosmos Health Reports Record Nine-Month Revenue of $53.6 Million, Up 18%; Q3 Gross Margin Up 465 Basis Points Sequentially; Total Debt Down 34% and Stockholders' Equity Up 21% Since Year-End
Nov 18, 2026, 9:31 AM EST1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The results show revenue growth and margin recovery (revenue mechanism) alongside a materially stronger balance sheet after the ATW note settlement (improves cash-flow/financing flexibility). Continued subscription and contract-manufacturing momentum could support longer-term revenue, but near-term non-cash charges still drive GAAP losses.
AI summary
What happened, with direct paths to the underlying reporting
Cosmos Health reported record nine-month revenue of $53.59M (up 17.6%), sequential gross-margin improvement to 12.6%, and a 33.8% reduction in total debt driven by early settlement of an $8.0M convertible note; contract-manufacturing backlog exceeded 32.7M units.
Nine-month revenue reached $53.59 million, up 17.6% from $45.57 million in the first nine months of 2025.
Q3 gross margin rebounded to 12.6%, up 465 basis points from 7.96% in Q2 2026.
Total debt declined 33.8% to $12.83 million year-to-date, primarily reflecting the full settlement of the $8.0 million ATW convertible note.
Cana Laboratories' contract manufacturing pipeline grew to a record of more than 32.7 million units, representing over $20 million in implied revenue and over $18 million in implied gross profit.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event